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ABSTRACT
The majority of borderline ovarian tumours (BOTs) behave in a benign fashion, 
but some may show aggressive behavior. The reason behind this has not been 
elucidated. The epidermal growth factor receptor (EGFR) is known to contribute to 
cell survival signals as well as metastatic potential of some tumours. EGFR expression 
and gene status have not been thoroughly investigated in BOTs as it has in ovarian 
carcinomas. In this study we explore protein expression as well as gene mutations 
and amplifications of EGFR in BOTs in comparison to a subset of other epithelial 
ovarian tumours.
We studied 85 tumours, including 61 BOTs, 10 low grade serous carcinomas 
(LGSCs), 9 high grade serous carcinomas (HGSCs) and 5 benign epithelial tumours. 
EGFR protein expression was studied using immunohistochemistry. Mutations were 
investigated by Sanger sequencing exons 18-21 of the tyrosine kinase domain of 
EGFR. Cases with comparatively higher protein expression were examined for gene 
amplification by chromogenic in situ hybridization. We also studied the tumours for 
KRAS and BRAF mutations.
Immunohistochemistry results revealed both cytoplasmic and nuclear EGFR 
expression with variable degrees between tumours. The level of nuclear localization 
was relatively higher in BOTs and LGSCs as compared to HGSCs or benign tumours. 
The degree of nuclear expression of BOTs showed no significant difference from that 
in LGSCs (mean ranks 36.48, 33.05, respectively, p=0.625), but was significantly 
higher than in HGSCs (mean ranks: 38.88, 12.61 respectively, p< 0.001) and benign 
tumours (mean ranks: 35.18, 13.00 respectively, p= 0.010). Cytoplasmic expression 
level was higher in LGSCs. No EGFR gene mutations or amplification were identified, 
yet different polymorphisms were detected. Five different types of point mutations 
in the KRAS gene and the V600E BRAF mutation were detected exclusively in BOTs 
and LGSCs.
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Our study reports for the first time nuclear localization of EGFR in BOTs. The 
nuclear localization similarities between BOTs and LGSCs and not HGSCs support 
the hypothesis suggesting evolution of LGSCs from BOTs. We also confirm that EGFR 
mutations and amplifications are not molecular events in the pathogenesis of BOTs.
INTRODUCTION
Borderline ovarian tumours (BOTs) are a 
heterogeneous group of tumours, comprising up to 
10% of ovarian epithelial neoplasms [1]. Serous and 
mucinous varieties constitute the majority of BOTs and 
unlike ovarian carcinoma, they occur mostly in women of 
reproductive age [2]. The majority of BOTs behave in a 
benign fashion, yet there remain a percentage of tumours 
that may recur or progress in a manner similar to malignant 
tumours [3]. To date there are no definite clinical or 
molecular markers that can help identify high risk BOTs 
that may behave in an aggressive fashion. Identification 
of risk factors for tumour progression is a challenge that 
can only be addressed effectively if the pathogenesis of 
these tumours is revealed. Mutations in KRAS and BRAF 
genes have been extensively studied in BOTs, but it is not 
known whether these mutations alone are sufficient to 
induce BOTs in vivo [4]. Epidermal growth factor receptor 
(EGFR) is a trans-membrane receptor with tyrosine kinase 
activity that is important in cell growth and proliferation 
[5]. It is the main regulator of downstream molecules 
in a number of pathways including the RAS and RAF 
genes [6]. EGFR plays a role in cell survival signals as 
well as in epithelial to mesenchymal transition of tumour 
cells, angiogenesis and subsequent metastasis [7]. EGFR 
amplification, mutations and overexpression have been 
extensively and variably reported in ovarian carcinoma 
[8]. Increased EGFR expression has been correlated 
with poorer patient outcomes in some studies [8, 9]. As 
a consequence, EGFR has been a subject of investigation 
for targeted therapies, with monoclonal antibodies and 
small-molecule tyrosine kinase inhibitors, exploring it as a 
potential therapeutic agent in ovarian carcinoma. Very few 
reports included BOTs and mostly investigated a small 
number of tumours or studied a single aspect (protein 
expression or mutations only).
In this work, we studied EGFR protein expression, 
gene mutations and gene copy number in a large series of 
BOTs, to investigate whether EGFR plays a role in the 
pathogenesis of these tumours. We also aimed to explore 
any possible relation between EGFR protein expression 
and / or gene status and the presence of KRAS and BRAF 
mutations.
RESULTS
We studied formalin fixed paraffin embedded 
tissues (FFPE) from eighty five cases of ovarian tumours 
including: 61 BOTs (including 45 serous, 14 mucinous, 1 
endometrioid and 1 seromucinous), 10 low-grade serous 
carcinomas (LGSCs), 9 high grade serous carcinomas 
(HGSCs) and 5 benign epithelial tumours (2 serous 
cystadenomas and 3 mucinous cystadenomas).
EGFR expression by immunohistochemistry
Two distinct patterns of protein expression; nuclear 
and cytoplasmic, were detected in all tumour categories, 
Figure 1. No membranous staining was detected in any 
of the tumours. Using two different scoring systems 
(discussed in Methods), we compared the degree of 
nuclear and cytoplasmic expression between different 
tumour groups. Using the first scoring system (the H 
score [10], Table 1), we found that the level of nuclear 
expression in BOTs was significantly higher compared to 
HGSCs (mean ranks: 38.88, 12.61 respectively, p< 0.001) 
and compared to benign tumours (mean ranks: 35.18, 
13.00 respectively, p= 0.010). On the other hand, no 
statistically significant difference existed between the level 
of nuclear positivity of BOTs and LGSCs (mean ranks 
36.48, 33.05, respectively, p= 0.625). Combining BOTs 
and LGSCs as one category, their nuclear expression level 
came again higher in comparison to HGSCs (mean ranks: 
43.74, 14.94, p< 0.001) and benign tumours (mean ranks: 
40.11, 15.70, p= 0.017). This pattern of nuclear expression 
similarity between BOTs and LGSCs did not apply to 
cytoplasmic expression, where positive cytoplasmic 
expression in LGSCs came higher compared to all other 
tumour categories; BOTs (mean ranks: 52.00, 33.38, p= 
0.008), HGSCs (mean ranks: 13.6, 6.0, p= 0.003), and 
benign tumours (mean ranks: 10.50, 3.00, p= 0.002).
To further validate these results we employed 
a second scoring system that was used by Lo et al [11] 
(table 1, detailed in Methods); where only the percentage 
of positive cells is considered, regardless of the intensity 
of expression. This scoring system similarly showed no 
statistically significant difference between BOTs and 
LGSCs (mean ranks: 36.57, 32.55, p=0.567), while the 
there was a significant difference between BOTs and 
HGSCs (mean ranks: 38.96, 12.06, p< 0.001) and benign 
tumours (mean ranks: 35.17, 13.10, p= 0.013).
EGFR, BRAF and KRAS gene mutation analysis
No functional mutations (i.e. mutations altering gene 
product) in EGFR were detected in any of the tumours, 
yet sequence analysis revealed the presence of rs1050171, 
c.2361 G>A single nucleotide polymorphism (SNP) in 
exon 20. The genotypes GG (wild), GA (heterozygous) and 
AA (homozygous) were detected at different frequencies 
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in different tumour groups Table  2 and Figure 2, 2A. In 
exon 21, three different single nucleotide substitutions 
were detected. These were the rs2229066, c.2508 C>T 
(in heterozygosity), detected in a total of 6 samples, a 
heterozygous rs41420046, c.2487 G>A in a serous BOT 
and the COSM26129, c.2572 C>T, L858L was identified 
in a different sample of serous BOTs (Figure 2, 2B-2D). 
Exons 18 and 19 were free from any molecular variation.
KRAS and BRAF mutations were detected 
exclusively in BOTs and LGSCs. For KRAS, five types of 
single substitutions in codons 12 and 13 were found, the 
most frequent was the G12D (19.7% in BOTs and 40% 
of LGSCs cases). The BRAF V600E mutation in exon 15 
was detected in 24.6% of BOTs and 40% of LGSCs. No 
concurrent mutations of both KRAS and BRAF existed in 
any case. Table 2 shows the frequencies of all mutational 
analysis findings among the studied groups.
No significant association was found between the 
mean of nuclear expression of EGFR and the presence 
of mutation (p= 0.384), BRAF mutations (p= 0.553) or 
combined KRAS and BRAF (p= 0.598).
EGFR gene amplification analysis by CISH
To ascertain whether high EGFR expression 
was related to EGFR gene amplification, we assessed 
amplification status in a subset (18 cases) of tumours 
that showed the highest expression using H score), which 
included 16 BOTs and 2 LGSCs. None of the cases 
showed gene amplification or aneuploidy. The range of 
EGFR gene copy number (GCN) in all cases was (1.16- 
2.30), median= 1.65, (Figure 3).
DISCUSSION
The results of our study show the presence of nuclear 
localization of EGFR in ovarian tumours particularly in 
BOTs and LGSCs. The level of nuclear localization was 
higher in BOTs and LGSCs as compared to HGSCs or 
benign tumours. To our knowledge, this is the first report 
of nuclear expression of EGFR in BOTs, while it has 
been previously reported in some malignant tumour types 
including ovarian [12] and breast carcinoma[11, 13]. 
Xia et al conducted an immunohistochemical analysis 
for EGFR on 221 primary ovarian carcinomas of mixed 
grades, and he reported a 28.3% nuclear positivity among 
his cohort, and showed that nuclear expression correlated 
with low survival rates. Nuclear transport of EGFR family 
receptors has been previously reported, exerting several 
functions; mainly as a co- transcriptors and regulators of 
cyclin D1 promoter [14, 15].
In addition, different molecular and clinicopatho-
logic studies suggest the evolution of LGSCs from BOTs, 
mostly through similarity in frequency of KRAS and BRAF 
mutations [4]. Our results showing significantly higher 
nuclear expression among these two categories compared 
to HGSCs and benign tumours, provide further support to 
this developmental relationship between serous BOTs and 
Figure 1: Expression of EGFR by immunohistochemistry in ovarian tumours A, B. a case of BOT showing moderate 
nuclear expression; [A: magnification x10; B: magnification; x20]. C, D. a BOT case showing nuclear expression of variable intensity [C: 
magnification x20; D: magnification x40]. E. a BOT case showing strong nuclear and moderate cytoplasmic expression [magnification 
x20]. F. a BOT case with negative nuclear staining and weak cytoplasmic expression [magnification x20].
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LGSCs, which is distinct from that of HGSCs [16, 17]. 
This also raises the possibility that EGFR may play a role 
in the pathogenesis of BOT-LGSC via nuclear localization, 
with no such role in the development of HGSCs.
Previous reports on the level of expression of 
membranous or cytoplasmic EGFR showed much 
variability, which may be due to differences in tissue 
preparation and fixation, different antibodies and staining 
protocols, but most importantly due to the great variability 
in scoring systems adopted. For our study we adopted the 
modified H- score method as it takes into consideration 
both percentages of cells showing expression as well as 
the intensity of the positive expression. We detected EGFR 
cytoplasmic expression in our cohort of tumours with 
variable distributions and intensity, where LGSCs showed 
the highest level of expression. In agreement with our results, 
Chen et al, showed that cytoplasmic EGFR positivity in both 
borderline and malignant ovarian tumours was significantly 
higher than in normal ovarian tissue and benign tumours 
[18]. Similarly, Nielsen et al reported that 67% of BOTs and 
62% of ovarian carcinomas showed cytoplasmic positivity 
[19]. In contrast, Fujiwara et al, reported 0% positivity in his 
10 studied BOTs, while 39.3% of the 152 serous carcinomas 
showed positive cytoplasmic staining [20]. Brustmann et 
al also reported no EGFR immune-reactivity in any of the 
serous cystadenomas or serous BOTs studied, compared to 
64% of serous carcinomas [21]. In addition, van Haaften-
Day compared the expression of EGFR in 16 invasive 
ovarian carcinomas and 11 serous borderline tumours and 
found that EGFR was expressed in a significantly greater 
fraction of malignant lesions (69%, n=16) than borderline 
lesions (18%, n=11) (p< 0.004) [22].
Our study shows that these patterns of EGFR 
expression are not related to underlying gene mutations 
or gene amplifications. In agreement with results of 
previous studies, our results confirm the rarity of EGFR 
mutations in BOTs [23, 24, 25]. However, we identified 
polymorphisms that have not been previously reported 
in ovarian tumours. Although being germline changes, 
some of these polymorphisms were previously reported 
to carry a potential relevance as prognostic markers. 
The identified rs1050171 polymorphism in exon 20 was 
previously reported to be associated with positive response 
to treatment with tyrosine kinase inhibitors (TKIs) in some 
cases of small cell carcinoma of the lung [26]. On the 
other hand, it was associated with worse survival rate in 
some oesophageal squamous cell carcinoma cases [27]. 
In addition, COSM26129 has only been described before 
in 3 cases of head and neck squamous cell carcinoma in 
2007 [28]; our study is the second to report this variation 
and the first to report its presence in a case of serous BOT.
We detected KRAS and BRAF mutations exclusively 
in BOTs and LGSCs in our cohort and in frequencies 
comparable to previous reports for both KRAS (17-41%) 
Table 1: Mean ranks and p values obtained from comparing H- score [10] and Lo et al [11] score of EGFR 
expression in cases from two tumour categories (Group1 vs Group2)
Group 1 Group 2 H- score Lo et al score
Mean rank 
(group 1)
Mean rank 
(group 2)
p value Mean rank 
(group 1)
Mean rank 
(group 2)
p value
Nuclear scoring results:
BOTs LGSCs 36.48 33.05 p= 0.625 36.57 32.55 p= 0.567
BOTs HGSCs 38.88 12.61 p< 0.001 38.97 12.06 p< 0.001
BOTs Benign 35.18 13.00 p= 0.010 35.17 13.10 p= 0.013
BOTs and LGSC HGSCs 43.74 14.94 p< 0.001 43.85 14.11 p< 0.001
BOTs and 
LGSCs Benign 40.11 15.70 p= 0.017 40.11 15.17 p= 0.016
Cytoplasmic scoring results:
BOTs LGSCs 33.38 52.00 p= 0.008 34.20 47.00 p= 0.026
BOTs HGSCs 36.21 30.67 p= 0.442 34.89 39.67 p= 0.437
BOTs Benign 34.77 18.00 p= 0.059 34.52 21.10 p= 0.085
LGSCs HGSCs 13.6 6.00 p= 0.003 11.00 8.89 p= 0.126
LGSCs Benign 10.50 3.00 p= 0.002 9.50 5.00 p= 0.009
The Mann- Whitney’s test is used in comparing the means of nuclear and cytoplasmic staining percentages between 
different groups. Significant differences are highlighted (p ≤ 0.05).
BOTs: borderline ovarian tumours, HGSCs: high grade serous carcinomas, LGSCs: low grade serous carcinomas
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and BRAF (30-71%) [6, 29–34]. Also in concordance with 
previous reports [32], KRAS and BRAF mutations were 
mutually exclusive in our study. We found no association 
between the level of expression of EGFR protein and 
KRAS and BRAF gene status. Szablewski et al [35] studied 
KRAS and BRAF mutations as well as EGFR expression 
in intestinal-type adenocarcinoma. Their results showed 
that KRAS mutations were frequent (42.9%) as was EGFR 
overexpression (63% of 43 samples), but similar to our 
findings, no statistically significant correlation between 
KRAS gene status and EGFR level of protein expression 
was detected.
Neither EGFR gene amplifications nor aneuploidy 
were detected in any of the BOTs or LGSCs we studied. 
Comparable results were reported by Dekanić et al, who 
reported a strong nuclear EGFR expression in colorectal 
carcinomas that was associated with cyclin-D1 but not 
with EGFR gene amplification [36]. But in contrast to 
these results, Lee et al found an increased copy number of 
the EGFR gene in 8.3% of BOTs and 37.8% of malignant 
tumours, but none in benign tumours [37].
The rarity of mutations and low frequency of 
EGFR polymorphisms detected and the lack of obvious 
amplification among our cohort suggests that these 
are not likely to be significant molecular events in the 
pathogenesis of BOTs or LGSCs. The high level of EGFR 
protein expression may be the result of other epigenetic 
or post transcriptional events rather than gene mutation or 
amplification.
Table 2: Gene mutations and polymorphisms
Borderline ovarian 
tumors
n (%) (2)
Low grade 
serous 
carcinoma
n (%) (2)
High grade 
serous 
carcinoma
n (%) (2)
Benign 
epithelial 
tumors
n (%) (2)
Gene Tumor
EGFR(1)
rs1050171 c.2361 
G>A (exon 20)
Wild (G) 15 (24.6) 1 (10) 1 (11.1) 0 (0)
Homozygous (A) 16 (26.2) 2 (20) 4 (44.4) 4 (80)
Heterozygous (R) 30 (49.2) 7 (70) 4 (44.4) 1 (20)
rs2229066 c.2508 C>T (exon 21) 5 (8.2) (4 serous, 1 mucinous) 1 (10) 0 (0) 0 (0)
rs41420046 c.2487 G>A (exon 21) 1 (1.6) serous 0 (0) 0 (0) 0 (0)
COSM26129 c.2572 C>T, (exon 21)
L858L 1 (1.6) serous 0 (0) 0 (0) 0 (0)
KRAS(1)
c.34G>T
G12C
3 (4.9) (2 serous,1 
mucinous) 1 (10) 0 (0) 0 (0)
c.35G>A
G12D
12 (19.7) (8 serous, 4 
mucinous) 4 (40) 0 (0) 0 (0)
c.35G>C
G12A
1 (1.6) (0 serous, 1 
mucinous) 0 (0) 0 (0) 0 (0)
c.35G>T
G12V
6 (9.8) 3 serous, 
2 mucinous, 1 
seromucinous)
1 (10) 0 (0) 0 (0)
c.37G>A
G13S
1 (1.6) (1 serous, 0 
mucinous) 0 (0) 0 (0) 0 (0)
Total of KRAS mutations 23 (37.7) 6 (60) 0 (0) 0 (0)
BRAF(1)
T>A 15 (24.6) 15 serous, 0 mucinous 4 (40) 0 (0) 0 (0)
(1): No concurrent mutations of both KRAS and BRAF existed in any case. (2) :Percentages do not add up to 100 due to cases 
without mutation/SNP
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MATERIALS AND METHODS
Selection of cases and ethical approvals
Tumour cases were retrieved from the Department 
of Histopathology, Hammersmith Hospital, London, UK. 
Slides from each case were reviewed and a representative 
block was selected with tumour content of at least 75%. 
The study was approved by The Hammersmith and Queen 
Charlotte’s & Chelsea Research Ethics Committee.
EGFR immunohistochemistry
Tissue sections of 5 μm thick were mounted 
on pre-coated slides, deparaffinised with xylene and 
rehydrated with graded ethanol. Endogenous peroxidase 
Figure 2: Representative chromatograms of mutations/SNPs revealed from sequences analysis of EGFR by Sanger 
sequencing. Red arrows point to the site of mutations/SNPs: A. rs1050171, c.2361 G> A, exon 20. B. rs17290559, c.2508 C>T, exon 21. 
C. rs41420046, c.2487 G>, exon 21. D. COSM26129 c.2572 C>T (p.L858L), exon 21. These molecular variations were detected only in 
exons 20 and 21 among BOTs and LGSC.
Figure 3: Representative images for the results of Chromogenic In situ hybridization (CISH) using EGFR specific 
probe A. a case of LGSC and B. a case of BOT showing no EGFR gene amplification/ aneuploidy [magnification x40]. Six or more brown 
dots in the nucleus in more than 50% of tumour cells indicate amplification of the EGFR gene, while 3-5 are considered aneuploidy.
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was blocked with Peroxidase Blocking Solution (DAKO, 
CA, USA) for 15 minutes. Sections were then incubated 
with primary antibody for EGFR (1:100, Clone: H11, 
Monoclonal Mouse Anti-Human, EGFR, Dako) [38] for 
overnight at 4°C. Positive controls were included for 
each run (Normal placental tissue) and a negative control 
slide was used for each case, as a duplicate section, 
where the antibody was replaced by antibody diluent. 
The reaction was visualised using Novolink™ Polymer 
Detection Systems (Leica Biosystems Newcastle Ltd, 
UK). Sections were counterstained with Haematoxylin. 
The stained slides were evaluated by two investigators 
(RS and ME) by light microscopy, using low (×10) 
and high (×20 or ×40) magnification. Discordant cases 
were jointly reviewed and a consensus was reached. 
The subcellular distribution of the staining between 
membrane, cytoplasm and nucleus was evaluated. For 
each case, reviewing the whole tumourous section, the 
percentage of positive cells and intensity of staining 
was estimated in each compartment. EGFR protein 
expression was scored in two different ways. First, using 
The H-score [10], which is the product of multiplication 
of the percentage of cells positive for membranous 
and cytoplasmic or positive for nuclear EGFR and the 
staining intensity, each producing a number (from 0 
to 300), for both nuclear and cytoplasmic expression. 
Cytoplasmic or nuclear scoring was then graded as 
follows: grade 1 (score 0–100), grade 2 (101–200), and 
grade 3 (201–300). This was followed by calculating a 
combined score for cytoplasmic and nuclear together, 
ranging 2-6. The other scoring system considered only 
the percentage of positive cells regardless of the intensity, 
described by Lo et al [11], in which membranous or 
cytoplasmic EGFR staining was grouped into four 
groups: high (3, >50%), moderate (2, 26-50%), low (1, 
1-25%), and negative (0, 0%), while nuclear EGFR was 
scored as high (3, >35%), moderate (2, 18-35%), low (1, 
1-17%), and negative (0, 0%) as previously described.
Mutation analysis using sanger sequencing
DNA extraction
Sections of 5-10 µm thickness were cut from FFPE 
tissue samples. Tumour tissue was scraped from at least 
5 slides per case and genomic DNA was subjected to 
overnight digestion with sodium dodecyl sulphate and 
proteinase K (Sigma-Aldrich, USA) at 37°C, followed 
by standard phenol-chloroform (1: 1) extraction and 
ethanol precipitation. The precipitant was suspended in 
35 μl of 10 mM Tris-Cl, of pH equals to 8.0. The quality 
of the genomic DNA was checked (OD A260/A280 
> 1.7) spectrophotometrically, using NanoDrop 1000 
Spectrophotometer V3.7, Thermo SCIENTIFIC.
Polymerase chain reaction (PCR) for EGFR, 
KRAS and BRAF
Mutation analysis of exons 18-21 of tyrosine kinase 
domain of EGFR, exon 2 (codons 12 and 13) of KRAS and 
exon 15 of BRAF genes were performed by Polymerase 
chain reaction (PCR) amplification followed by direct 
sequencing of the PCR products. The primers used were 
provided from custom oligos, invitogen, life technologies 
TM and are listed in Table 3.
For EGFR, DNA was amplified in a total volume 
of 30 μl containing 1.5 mM MgCl2, 1.25 U of Ampli Taq 
Gold ® DNA, 3 µl of GeneAmp 10x PCR buffer II (ABI 
Cat N808-0241), 200 μM of each dNTP (dATP, dCTP, 
dGTP and dTTP; Promega, Cat U1410), 300 nM of each 
primer and 250 ng of DNA. DNA was first denatured at 
95°C for 5 minutes, followed by 38 cycles of PCR including 
denaturation at 95°C for 45 s, annealing for 45 s at 60°C 
and extension for 45 s at 72°C. At the end of the last cycle, 
the mixture was incubated at 72°C for 10 minutes. As for 
KRAS and BRAF, each PCR reaction was performed in a 25 
μl volume mixture containing 250 ng of genomic DNA, 2.5 
μl of both forward and reverse primers (0.1 μmol each) and 
12.5 μl of GoTaq®Hot Start Green Master Mix (Promega). 
PCR amplification was carried out using the following 
conditions: 1 cycle at 95°C (15 minutes); 35 cycles at 94°C 
(30 seconds), at 52°C for KRAS and 50 °C for BRAF(30 
seconds), and at 72°C (30 seconds), and a final extension 
step at 72°C (7 minutes). All PCR reactions were performed 
in G- storm thermal cycler (Somerton Biotechnology Centre, 
UK). PCR amplicons were then checked using Qiaxcel 
capillary electrophoresis, where negative controls (non-
template sample) were used and blood lymphocyte DNA 
from a healthy individual was used as a positive control of 
the amplification.
Table 3: Primers’ sequences used for amplification of EGFR (exons 18-21), KRAS (exon 2) and BRAF (exon 15)
Gene Forward primer (5’-3’) Reverse primer (5’-3’)
EGFR, exon 18 TTGTCCTTCCAAATGAGCTG ACAGCTTGCAAGGACTCTGG)
EGFR, exon 19 AGATCACTGGGCAGCATGT CAGCTGCCAGACATGAGAAA
EGFR, exon 20 CATTCATGCGTCTTCACCTG CATATCCCCATGGCAAACTC
EGFR, exon 21 ATCCTCCCCTGCATGTGTTA CTCAGAGCCTGGCATGAAC
KRAS, exon 2 (codon 12 and 13 GTGTGACATGTTCTAATATAGTCA CTGTATCAAAGAATGGTCCTGCAC
BRAF, exon 15 TCATAATGCTTGCTCTGATAGG GGCCAAAAATTTAATCAGTGG
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Sanger sequencing for EGFR, KRAS and BRAF
PCR products were then purified using the QIAquick 
PCR Purification Kit (Qiagen, Crawley UK) according to 
manufacturer’s instructions. All purified PCR products 
were then sequenced in both orientations by Sanger 
sequencing using the manufacturers’ recommendations. 
Sequencing reactions were run on 3500Xl Genetic 
analyser (life technologies), and then purified using Big 
DyeSAM Solution and Big DyeXterminator solution (life 
technologies), to eliminate the excess of labelled ddNTPs. 
The sequence alignments were done with the BioEdit 
Sequence Alignment Editor and analysed using SeqScape 
software 2.5 (Applied Biosystems). The DNA sequence 
of EGFR gene was obtained from GenBank (EGFR-
001, transcript ID: ENST00000275493). We compared 
the KRAS sequence against (KRAS-001, transcript ID: 
ENST00000311936), and BRAF sequence against (BRAF-
001, transcript ID: ENST00000288602) as in Gene Bank. 
Detected mutations/polymorphisms were confirmed by at 
least two independent PCR amplifications and repeated 
sequencing reactions.
Chromogenic in-situ hybridization (CISH) 
for EGFR
EGFR gene amplification was investigated by CISH 
in a subset of 18 cases which showed the highest combined 
H score expression. We aimed to investigate cases with 
scores of 6, 5 and 4 with at least a score of 2 in each of 
cytoplasmic and nuclear compartments. Score 6 was not 
detected in any of the studied cases. Cases studied with 
CISH included the 2 cases of BOTs which showed a score 
of 5 and 16 cases with score 4 (14 BOTs and 2 LGSCs). 
CISH was performed as previously described [39]. CISH 
was performed on 3 µm- thick FFPE tumour sections 
using ZytoDot CISH Implementation Kit, ZytoVision 
GmbH, Germany. Briefly, Slides were deparaffinised in 
xylene and immersed in 100% ethanol followed by water. 
Slides were then immersed in pre-treatment solution at 98 
°C for 17 minutes, then immediately washed with distilled 
water for 3 washes, 2 minutes each. Enzymatic digestion 
was done by incubating the slides with pepsin (2-3 drops) 
for 6 minutes at room temperature. The slides were then 
washed, dehydrated and air dried. Application of 15µl 
of the ready to use probe, (ZytoDot SPEC EGFR Probe, 
ZytoVision GmbH, Germany) was followed by application 
of coverslips, sealing of the edges and denaturing at 95 
°C for 5 minutes and hybridization at 37 °C overnight 
in SPOT-Light®CISH™ Hybridizer (Invitrogen, life 
technologies). On the next day, a stringent wash was 
performed using 5× standard saline citrate (SCC) at 75° C 
for 7 minutes, followed by washing twice for 2 minutes. 
Sections were blocked with 3% H2O2, diluted with 
methanol for 10 minutes and PBS wash was performed 
twice for 2 minutes. Non-specific binding was blocked by 
applying the blocking solution and by incubating for 10 
minutes. After incubation with a Mouse anti-Dig antibody 
for 30 minutes at room temperature, the procedure was 
continued by incubation with Anti mouse HRP-polymer 
and substrate chromogenic solution (DAB) for 30 minutes 
and counterstained with haematoxylin for 5s. The tissues 
were dehydrated in ethanol and coverslipped in mounting 
solution.
Slides were examined by light microscopy. The CISH 
signals were seen as dark brown dots. We counted 60 nuclei 
with a high power (x40) objective. Also the average EGFR 
GCN per nucleus for each tissue section was calculated 
[40]. A GCN of six or more in the nucleus in more than 50% 
of tumour cells indicate the presence of amplification of the 
EGFR gene, while 3-5 gene copies in > 50% of studied cells 
were considered aneuploidy. CISH scoring was evaluated 
by three researchers (RS, ML and RN).
Statistical analysis
Statistical analysis was performed using SPSS 18. 
Mann-Whitney Test was used for 2 group comparison.
Results were considered significant when p value < 0.05.
CONCLUSION
This is the first study to thoroughly investigate the 
gene status and protein expression of EGFR in BOTs. Our 
study showed that nuclear expression of EGFR in BOTs 
and LGSCs was significantly higher compared to HGSCs 
or benign tumours, which lends support to the molecular 
similarity between BOTs and LGSCs. While EGFR 
gene mutation and amplification was not detected, gene 
polymorphisms were identified, which may have potential 
clinical significance.
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